ResearcherAsan Medical CenterNo recent work listed
Jaewon Hyung
Matched on ORCID iD 0000-0002-0680-4486; OpenAlex author ID A5060912167. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 1 paper
Papers 4
- Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Dam… Co-author DOI 10.4143/crt.2023.452↗
- Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIR… Co-author DOI 10.1016/j.esmoop.2022.100484↗
- Current status and future perspective of neoadjuvant therapy in locally advanced and borderline resectable pancreatic adenocarcinoma: a narrative review. Co-author DOI 10.21037/cco-21-166↗
- Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biom… Co-author DOI 10.1038/s41416-020-0867-x↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dae Wook Hwang · 4 shared papers, 2020–2023 · strength 0.56
- Paper Current status and future perspective of neoadjuvant therapy in locally advanced and borderline resectable pancreatic a… DOI 10.21037/cco-21-166↗
- Paper Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified F… DOI 10.4143/crt.2023.452↗
- Paper Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally adv… DOI 10.1016/j.esmoop.2022.100484↗
- Changhoon Yoo · 4 shared papers, 2020–2023 · strength 0.56
- Paper Current status and future perspective of neoadjuvant therapy in locally advanced and borderline resectable pancreatic a… DOI 10.21037/cco-21-166↗
- Paper Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified F… DOI 10.4143/crt.2023.452↗
- Paper Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally adv… DOI 10.1016/j.esmoop.2022.100484↗
- Kyu‐pyo Kim · 3 shared papers, 2020–2023 · strength 0.43
- Paper Current status and future perspective of neoadjuvant therapy in locally advanced and borderline resectable pancreatic a… DOI 10.21037/cco-21-166↗
- Paper Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified F… DOI 10.4143/crt.2023.452↗
- Paper Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinom… DOI 10.1038/s41416-020-0867-x↗
- Tae Jun Song · 3 shared papers, 2020–2023 · strength 0.38
- Paper Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified F… DOI 10.4143/crt.2023.452↗
- Paper Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally adv… DOI 10.1016/j.esmoop.2022.100484↗
- Paper Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinom… DOI 10.1038/s41416-020-0867-x↗
- Jin‐hong Park · 2 shared papers, 2020–2022 · strength 0.27
- Paper Current status and future perspective of neoadjuvant therapy in locally advanced and borderline resectable pancreatic a… DOI 10.21037/cco-21-166↗
- Paper Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinom… DOI 10.1038/s41416-020-0867-x↗
- Sang Soo Lee · 2 shared papers, 2020–2022 · strength 0.27
- Paper Current status and future perspective of neoadjuvant therapy in locally advanced and borderline resectable pancreatic a… DOI 10.21037/cco-21-166↗
- Paper Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinom… DOI 10.1038/s41416-020-0867-x↗
- Ki Byung Song · 2 shared papers, 2020–2023 · strength 0.24
- Paper Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified F… DOI 10.4143/crt.2023.452↗
- Paper Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinom… DOI 10.1038/s41416-020-0867-x↗
- Do Hyun Park · 2 shared papers, 2020–2023 · strength 0.24
- Paper Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified F… DOI 10.4143/crt.2023.452↗
- Paper Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinom… DOI 10.1038/s41416-020-0867-x↗
- Baek‐Yeol Ryoo · 2 shared papers, 2020–2023 · strength 0.24
- Paper Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified F… DOI 10.4143/crt.2023.452↗
- Paper Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinom… DOI 10.1038/s41416-020-0867-x↗
- Song Cheol Kim · 2 shared papers, 2020–2023 · strength 0.24
- Paper Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified F… DOI 10.4143/crt.2023.452↗
- Paper Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinom… DOI 10.1038/s41416-020-0867-x↗
- Dong-Hoon Lim · 1 shared paper, 2023 · strength 0.16
- Seung‐Mo Hong · 1 shared paper, 2023 · strength 0.16
- Hyunseok Yoon · 1 shared paper, 2023 · strength 0.16
- Jin Hee Kim · 1 shared paper, 2020 · strength 0.08
- Seung Soo Lee · 1 shared paper, 2020 · strength 0.08
- Woohyung Lee · 1 shared paper, 2020 · strength 0.08
- Myung‐Hwan Kim · 1 shared paper, 2020 · strength 0.08
- Dong Wan Seo · 1 shared paper, 2020 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.